Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

18.8%

9 terminated/withdrawn out of 48 trials

Success Rate

79.5%

-7.0% vs industry average

Late-Stage Pipeline

40%

19 trials in Phase 3/4

Results Transparency

34%

12 of 35 completed trials have results

Key Signals

2 recruiting12 with results7 terminated

Enrollment Performance

Analytics

Phase 4
13(33.3%)
Phase 2
8(20.5%)
N/A
7(17.9%)
Phase 3
6(15.4%)
Phase 1
5(12.8%)
39Total
Phase 4(13)
Phase 2(8)
N/A(7)
Phase 3(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials
NCT05994976Recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Role: lead

NCT06283550Phase 2Completed

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Role: lead

NCT05835843Completed

Study to Assess the Reliability of PASI Scoring Using Digital-Based Images

Role: lead

NCT04706962Phase 1Active Not Recruiting

TH1902 in Patients With Advanced Solid Tumors

Role: collaborator

NCT05602207Phase 4Completed

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Role: lead

NCT05844618Phase 4Completed

Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis

Role: lead

NCT06261021Phase 2Recruiting

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

Role: lead

NCT06101823Phase 2Unknown

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

Role: collaborator

NCT05491447Phase 2Terminated

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Role: collaborator

NCT02270411Completed

Inflammatory Cells From Various Pathologies

Role: lead

NCT04999839Phase 2Completed

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Role: collaborator

NCT03971643Phase 2Completed

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Role: collaborator

NCT05382819Phase 1Terminated

A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

Role: collaborator

NCT05499416Phase 4Withdrawn

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Role: lead

NCT03868098Phase 4Completed

Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis

Role: lead

NCT04537468Not ApplicableCompleted

Development of a Method to Measure mRNA Levels in Skin Samples

Role: lead

NCT03630939Phase 1Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

Role: collaborator

NCT03625219Not ApplicableCompleted

Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers

Role: lead

NCT03795402Completed

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

Role: collaborator

NCT02926807Completed

Trial on Vascular Inflammation in Atopic Dermatitis

Role: lead